EUCTR2015-001975-30-IT进行中（未招募）1 期
Global multicenter, open-label, randomized, event-driven, active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes - GALILEO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,644
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Man or woman of 18 years of age or older
- •Have a successful TAVR of a native aortic valve stenosis
- •Via iliofemoral or subclavian access
- •With any approved/marketed TAVR device
- •Provide written IC
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 152
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1368
排除标准
- •1. Any atrial fibrillation (AF), at the time of randomization or previous, with an ongoing indication for oral anticoagulant treatment
- •2. Any other indication for continued treatment with any oral anticoagulant (OAC)
- •3. Known bleeding diathesis, such as but not limited to:
- •a. active internal bleeding, clinically significant bleeding, bleeding at a non-compressible site, or bleeding diathesis,
- •b. platelet count = 50,000/mm3 at screening
- •c. Hemoglobin level < 8.5 g/dL
- •d. history of intracranial hemorrhage or subdural hematoma
- •e. major surgery, biopsy of a parenchymal organ, or serious trauma within 30 days before randomization
- •f. active peptic ulcer or known upper GI bleeding within the last 3 months
- •4. Any indication for dual-antiplatelet therapy (DAPT) for more than 3 months after randomization (such as coronary, carotid or peripheral stent implantation)
- •5. Known hypersensitivity or contraindication to acetylsalicylic acid, clopidogrel or rivaroxaban or hypersensitivity to contrast media that could not be solved neither by switching to an alternate contrast media nor with pre-treatment with appropriate medication
- •6. Routine use of oral non-steroidal anti-inflammatory drugs (NSAID)
- •7. Concomitant therapy with systemic drugs that are strong inhibitors of both CYP 3A4 and P-gp (azole antimycotics such as ketoconazole and itraconazole or HIV protease inhibitors such as ritonavir)
- •8. Concomitant therapy with drugs that are strong CYP 3A4 inducers
- •(e.g. carbamazepine, phenytoin, rifampin, St. John's wort)
- •9. Concomitant therapy with omeprazole or esomeprazole that cannot be switched to an alternate medication.
- •Concomitant conditions
- •10. Planned coronary or vascular intervention or major surgery
- •11. Clinically overt stroke within the last 3 months
- •12. Severe renal impairment (eGFR < 30 mL/min/1.73 m2) or on dialysis, or post-TAVR unresolved acute kidney injury with renal dysfunction stage 2 or higher
- •13. Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy
- •14. Active infective endocarditis
- •15. Active malignancy (diagnosed within 5 years) except for adequately treated non-melanoma skin cancer or other non-invasive or in situ neoplasm (e.g., cervical cancer in situ that has been successfully treated)
- •16. Dementia or forgetfulness hindering compliance with medication intake or other study procedures
- •17. Legally incompetent to provide IC
- •18. Previous (30 days before enrolment) or concomitant participation in another clinical study with investigational medicinal product(s).
- •19. Previous assignment to treatment during this study
- •20. Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g. employee or student of the investigational site) or sponsor
- •21. Female of childbearing potential
- •a. Who are not surgically sterile, or who are sexually active and not willing to use adequate contraceptive measures with a failure rate less than 1% per year (e.g. oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, male partner sterilization) before entry and throughout the study, or
- •b. For whom a negative pregnancy test is unavailable before study entry, or
- •c. Who are pregnant or breast feeding before study entry.
研究者
相似试验
进行中（未招募）
1 期
A study to compare rivaroxaban, following successful TAVR, to an antiplatelet drug and determine if it is superior in reducing death or first thromboembolic events (DTE) and non-inferior towards primary bleeding events (PBE).EUCTR2015-001975-30-ESBayer HealthCare AG1,520
进行中（未招募）
1 期
A study to compare rivaroxaban, following successful TAVR, to an antiplatelet drug and determine if it is superior in reducing death or first thromboembolic events (DTE) and non-inferior towards primary bleeding events (PBE).Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing bleeding riskMedDRA version: 18.1Level: PTClassification code 10002916Term: Aortic valve replacementSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-001975-30-BEBayer HealthCare AG1,520
进行中（未招募）
1 期
A study to compare rivaroxaban, following successful TAVR, to an antiplatelet drug and determine if it is superior in reducing death or first thromboembolic events (DTE) and the primary bleeding events (PBE).Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing bleeding riskMedDRA version: 19.1 Level: PT Classification code 10002916 Term: Aortic valve replacement System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-001975-30-DKBayer AG1,520
进行中（未招募）
1 期
A study to compare rivaroxaban, following successful TAVR, to an antiplatelet drug and determine if it is superior in reducing death or first thromboembolic events (DTE) and the primary bleeding events (PBE).Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing bleeding riskMedDRA version: 19.0 Level: PT Classification code 10002916 Term: Aortic valve replacement System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-001975-30-NLBayer AG1,520
进行中（未招募）
1 期
A study to compare rivaroxaban, following successful TAVR, to an antiplatelet drug and determine if it is superior in reducing death or first thromboembolic events (DTE) and non-inferior towards primary bleeding events (PBE).Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing bleeding riskMedDRA version: 18.1 Level: PT Classification code 10002916 Term: Aortic valve replacement System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-001975-30-NOBayer HealthCare AG1,520